Developer docs
API playgroundTry for free, no card

Search company profiles

Accell

Full company profile

uuid00083zp

Namestring
Accell
Legal namestring
Accell Clinical Research, LLC
Company typeenum
Private
Founded yearint
2007
Descriptiontext

Accell Clinical Research, LLC is a privately held, full-service Contract Research Organization (CRO) founded in 2007 by Natalia Nayanova and Julia Kondakov, headquartered operationally in St. Petersburg, Russia, with a contractual and legal entity in Culpeper, Virginia (USA) and a 2022-established European operations office in Bucharest, Romania. The company delivers Phase I–IV clinical trial management, functional outsourcing, strategic guidance and trial set-up, and rescue study services to global pharmaceutical and biotechnology sponsors executing trials in Eastern Europe, the Baltic states, the Balkans, the Caucasus, Central Asia, and the EAEU. A specialized sub-brand, Accell Oncology (launched 2018), positions the firm as the only oncology-focused CRO in Eastern Europe and Russia, supported by a network of 150+ oncology sites and 200+ cardiology sites; the company also operates the OncoForum online platform (launched 2019) for organizing virtual advisory boards with oncology key opinion leaders.

Revenue is generated through project-based professional services engagements, with quote-driven, non-publicly-disclosed pricing. Go-to-market is enterprise field sales executed by a Business Development team spread across the USA, UK, Romania, and the Netherlands, supported by heavy presence at industry conferences (ASCO, ESMO, BIO, CPHI, DIA, Nordic Life Science Days, Medidata NEXT). The customer base is concentrated in large global pharmaceutical sponsors and mid-to-large biotechnology companies, with case-study engagements spanning Phase III oncology, cardiology, gastroenterology, and onco-hematology programs. Differentiators include a physician-led team in which ~80% of clinical staff hold MD degrees, demonstrated recruitment rates 3–7x above rest-of-world benchmarks across multiple therapeutic areas, clean inspection records from EMA and Roszdravnadzor, and ICH E6 GCP compliance. Following the 2022 geopolitical events, the company has temporarily suspended new activities in Russia and Ukraine and is repositioning its operational base toward EU-domiciled delivery via Romania and the Syntax for Science partnership in Spain.

Short descriptiontext

Accell Clinical Research is a privately held, full-service CRO founded in 2007 that runs Phase I–IV clinical trials for global pharma and biotech sponsors across Eastern Europe, the Baltics, the Balkans, and Central Asia, with a specialized oncology division (Accell Oncology) and operations hubs in Russia, the USA, and Romania.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWarrenton, United States
HQ citystring
Warrenton
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical trial management, contract research organization, oncology clinical trials, patient recruitment services, site feasibility studies
Industry3 codes
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAGAAAI
Patient Recruitment, Site Feasibility & Trial Enablement CROs
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Other Scientific and Technical Consulting Services54169
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Contract Research Organization (Clinical Trial Services)
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Clinical Research Services
TypeProfessional Services
Description

Full-service CRO providing clinical trial management, site selection, regulatory affairs, and operational support for pharmaceutical and biotech sponsors. Project-based professional services across phases I-IV clinical trials.

accellclinical.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1Accell Oncology
Description

A specialized oncology-focused division of Accell Clinical Research, providing clinical trial services for solid tumors and hematologic tumors in Eastern Europe, Russia, and Ukraine. It also offers an online oncology platform called OncoForum for advisory boards and consultancy services with oncology key opinion leaders.

accellclinical.com
Core offering1 text field

Accell Clinical Research is a full-service Contract Research Organization (CRO) that manages Phase I-IV clinical trials for pharmaceutical and biotech sponsors across Eastern Europe, Russia, and CIS countries. Its core offerings include clinical trial management, functional outsourcing of clinical research staff, strategic guidance and trial set-up (feasibility, site selection, regulatory affairs), and rescue studies for delayed trials. Through its Accell Oncology sub-brand, it operates the only oncology-specialized CRO division in Eastern Europe and Russia, supplemented by the OncoForum online platform for virtual advisory boards with oncology key opinion leaders.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Accell Clinical Research is a full-service Contract Research Organization (CRO) that provides clinical trial services across Eastern Europe, Russia, and CIS countries. The company operates through its core service offerings (Clinical Trial Management, Functional Outsourcing, Strategic Guidance & Trial Set-up, and Rescue Studies) and a specialized oncology sub-brand called Accell Oncology. Accell Oncology, launched in 2018, is positioned as the only oncology-specialized CRO in Eastern Europe and Russia. Additionally, the company developed OncoForum, an online platform for organizing virtual oncology advisory boards with key opinion leaders. The company has offices in Russia (Saint Petersburg headquarters), USA (Virginia), and Romania (Bucharest), and maintains active operations across 10+ European and CIS countries.

Product and service6 records
1Clinical Trial Management
CategoryClinical Trial Services
Description

Full-service clinical trial management from planning to execution, including site management, monitoring, and project coordination, delivered to pharmaceutical and biotech sponsors running Phase I-IV trials.

2Functional Outsourcing
CategoryClinical Trial Services
Description

Provides clinical operational staff to join client teams as needed, offering flexible resource augmentation for clinical trials, including CRA and project management support on a functional basis.

3Strategic Guidance & Trial Set-up
CategoryClinical Trial Services
Description

Comprehensive strategic planning services including study feasibility, site selection, regulatory affairs, study documentation development, vendor selection, and investigator meeting organization for pharmaceutical and biotech sponsors.

4Rescue Studies
CategoryClinical Trial Services
Description

Specialized services to rescue failing clinical trials, including feasibility assessments, country expansion analysis, and functional outsourcing of clinical operational staff for sponsors facing delayed enrollment or operational issues.

5Accell Oncology
CategoryOncology CRO Services
Description

Specialized oncology-focused clinical trial services division of Accell, including solid tumor and hematologic malignancy trials, advisory boards, and consultancy services with oncology key opinion leaders, supported by a network of 150+ oncology sites.

6OncoForum
CategoryOncology Advisory Platform
Description

Online oncology platform for organizing advisory boards and providing consultancy services with oncology key opinion leaders (KOLs), enabling virtual meetings to obtain expert validation on medical and trial design topics for pharmaceutical and biotech clients.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
1Syntax for Science
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-11-01
Description

Strategic CRO partnership announced in November 2019 combining Accell's Eastern European expertise with Syntax's Spanish operations - described as 'East meets West' collaboration

accellclinical.com
2Wuhan National Bio-industry Base (Biolake)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2018-08-01
Description

Meeting with Chinese biotech industrial base delegation in St. Petersburg; Biolake expressed interest in collaboration given Accell's oncology expertise and connections with key opinion leaders in Eastern Europe

accellclinical.com
3American CRO Partner
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2017-07-01
Description

During Boston conference, Julia Kondakov and Maria Mezentseva visited American CRO's office to discuss partnership grounds; companies had collaborated on projects before

accellclinical.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2011-01-01
Description

Accell joined MPR's Global CRO Development Group strategic alliance with other regional CROs (Cromos Pharma, Fortis Clinical Research, Research Development RA) to expand scale, scope and geographic locations

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Part of MPR CRO Alliance - USA-based CEE CRO partner in the global strategic alliance

6Fortis Clinical Research (India)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Part of MPR CRO Alliance - India-based CRO partner in the global strategic alliance

accellclinical.com
7Research Development RA S.A. (South America)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Part of MPR CRO Alliance - South America-based CRO partner in the global strategic alliance

accellclinical.com
Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

US-based CRO focused on Central and Eastern Europe with similar regional specialization. Cromos is also a member of the same Maximax Global CRO Alliance with Accell, making it both a partner and the closest direct competitor for CEE oncology and multi-therapeutic trials.

TypeDirect peer
Description

Mid-size, full-service global CRO with comparable therapeutic-area focus (oncology, cardiology, CNS) and a similar emphasis on scientific quality and sponsor relationships. Directly competes for mid-cap biotech and large pharma Phase II-IV work.

TypeBroad incumbent
Description

Mid-to-large full-service CRO with strong therapeutic specialization and reputation for high-quality data. While larger and globally distributed, Medpace is a relevant comparable for Accell's physician-led, therapeutically-aligned operating model.

TypeBroad incumbent
Description

Largest global CRO with integrated technology, real-world data, and full Phase I-IV capabilities. Competes with Accell for enterprise pharma trials and increasingly absorbs regional specialists via acquisition, defining the upper-bound competitive threat.

TypeBroad incumbent
Description

Global full-service CRO formed via major consolidations (PRA merger), offering biotech and large pharma sponsors end-to-end clinical and post-approval services. Represents the scaled, technology-enabled alternative to Accell's regional specialist model.

TypeBroad incumbent
Description

Large global CRO with comprehensive Phase I-IV services and strong oncology/biotech franchise post EQT-Goldman take-private. Provides a useful scaled benchmark for what Accell would need to evolve into to compete for multinational trial RFPs.

TypeEmerging player
Description

Leading China-based CRO expanding internationally with comparable therapeutic specialization (oncology) and growing EU/US footprint. Represents an emerging non-Western competitor for global sponsors seeking cost-effective, regionalized trial execution.

8Fortis Clinical Research
TypeDirect peer
Description

India-based full-service CRO that is also a partner in the Maximax Global CRO Alliance with Accell. Comparable as a regional-specialist CRO serving global sponsors, with similar cost-arbitrage positioning and Phase I-IV offerings.

TypeBroad incumbent
Description

Large CRO and commercialization services provider offering end-to-end clinical development plus commercial solutions. Competitor for large enterprise pharma trial RFPs where Accell might serve as a regional sub-contractor.

TypeRegional player
Description

European CRO focused on early-phase and bioequivalence studies with strong presence in Germany and broader EU. Relevant as a regional European CRO comparable to Accell's EU expansion strategy post-Russia/Ukraine exit.

Market position
Strengths6 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Accell

Contract Research Organization (Clinical Trial Services)accellclinical.com

Accell Clinical Research is a privately held, full-service CRO founded in 2007 that runs Phase I–IV clinical trials for global pharma and biotech sponsors across Eastern Europe, the Baltics, the Balkans, and Central Asia, with a specialized oncology division (Accell Oncology) and operations hubs in Russia, the USA, and Romania.

What Accell does

Accell Clinical Research, LLC is a privately held, full-service Contract Research Organization (CRO) founded in 2007 by Natalia Nayanova and Julia Kondakov, headquartered operationally in St. Petersburg, Russia, with a contractual and legal entity in Culpeper, Virginia (USA) and a 2022-established European operations office in Bucharest, Romania. The company delivers Phase I–IV clinical trial management, functional outsourcing, strategic guidance and trial set-up, and rescue study services to global pharmaceutical and biotechnology sponsors executing trials in Eastern Europe, the Baltic states, the Balkans, the Caucasus, Central Asia, and the EAEU. A specialized sub-brand, Accell Oncology (launched 2018), positions the firm as the only oncology-focused CRO in Eastern Europe and Russia, supported by a network of 150+ oncology sites and 200+ cardiology sites; the company also operates the OncoForum online platform (launched 2019) for organizing virtual advisory boards with oncology key opinion leaders.

Revenue is generated through project-based professional services engagements, with quote-driven, non-publicly-disclosed pricing. Go-to-market is enterprise field sales executed by a Business Development team spread across the USA, UK, Romania, and the Netherlands, supported by heavy presence at industry conferences (ASCO, ESMO, BIO, CPHI, DIA, Nordic Life Science Days, Medidata NEXT). The customer base is concentrated in large global pharmaceutical sponsors and mid-to-large biotechnology companies, with case-study engagements spanning Phase III oncology, cardiology, gastroenterology, and onco-hematology programs. Differentiators include a physician-led team in which ~80% of clinical staff hold MD degrees, demonstrated recruitment rates 3–7x above rest-of-world benchmarks across multiple therapeutic areas, clean inspection records from EMA and Roszdravnadzor, and ICH E6 GCP compliance. Following the 2022 geopolitical events, the company has temporarily suspended new activities in Russia and Ukraine and is repositioning its operational base toward EU-domiciled delivery via Romania and the Syntax for Science partnership in Spain.

Accell firmographics

Firmographics
Name
Accell
Legal name
Accell Clinical Research, LLC
Website
https://accellclinical.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
11–50 employees
Short description
Accell Clinical Research is a privately held, full-service CRO founded in 2007 that runs Phase I–IV clinical trials for global pharma and biotech sponsors across Eastern Europe, the Baltics, the Balkans, and Central Asia, with a specialized oncology division (Accell Oncology) and operations hubs in Russia, the USA, and Romania.
Ownership category
akta.pro rank

Accell industry classification

Industry
Product category
Contract Research Organization (Clinical Trial Services)
NAICS
Scientific Research and Development Services (5417), Other Scientific and Technical Consulting Services (54169)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAGAAAI
Patient Recruitment, Site Feasibility & Trial Enablement CROs

Keywords

  • Clinical trial management
  • Contract research organization
  • Oncology clinical trials
  • Patient recruitment services
  • Site feasibility studies

Where Accell is headquartered

Location

Headquarters

HQ city
Warrenton
HQ country
United States
HQ region
North America

Offices4 records

Markets served

Accell business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Clinical Research Services: Full-service CRO providing clinical trial management, site selection, regulatory affairs, and operational support for pharmaceutical and biotech sponsors. Project-based professional services across phases I-IV clinical trials.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Accell product offering

Product offering

Core offering

Accell Clinical Research is a full-service Contract Research Organization (CRO) that manages Phase I-IV clinical trials for pharmaceutical and biotech sponsors across Eastern Europe, Russia, and CIS countries. Its core offerings include clinical trial management, functional outsourcing of clinical research staff, strategic guidance and trial set-up (feasibility, site selection, regulatory affairs), and rescue studies for delayed trials. Through its Accell Oncology sub-brand, it operates the only oncology-specialized CRO division in Eastern Europe and Russia, supplemented by the OncoForum online platform for virtual advisory boards with oncology key opinion leaders.

Product overview

Accell Clinical Research is a full-service Contract Research Organization (CRO) that provides clinical trial services across Eastern Europe, Russia, and CIS countries. The company operates through its core service offerings (Clinical Trial Management, Functional Outsourcing, Strategic Guidance & Trial Set-up, and Rescue Studies) and a specialized oncology sub-brand called Accell Oncology. Accell Oncology, launched in 2018, is positioned as the only oncology-specialized CRO in Eastern Europe and Russia. Additionally, the company developed OncoForum, an online platform for organizing virtual oncology advisory boards with key opinion leaders. The company has offices in Russia (Saint Petersburg headquarters), USA (Virginia), and Romania (Bucharest), and maintains active operations across 10+ European and CIS countries.

Differentiator

Problem solved

Functional benefit

Brands

  • Accell Oncology: A specialized oncology-focused division of Accell Clinical Research, providing clinical trial services for solid tumors and hematologic tumors in Eastern Europe, Russia, and Ukraine. It also offers an online oncology platform called OncoForum for advisory boards and consultancy services with oncology key opinion leaders.

Products and services

  • Clinical Trial Management Full-service clinical trial management from planning to execution, including site management, monitoring, and project coordination, delivered to pharmaceutical and biotech sponsors running Phase I-IV trials.
  • Functional Outsourcing Provides clinical operational staff to join client teams as needed, offering flexible resource augmentation for clinical trials, including CRA and project management support on a functional basis.
  • Strategic Guidance & Trial Set-up Comprehensive strategic planning services including study feasibility, site selection, regulatory affairs, study documentation development, vendor selection, and investigator meeting organization for pharmaceutical and biotech sponsors.
  • Rescue Studies Specialized services to rescue failing clinical trials, including feasibility assessments, country expansion analysis, and functional outsourcing of clinical operational staff for sponsors facing delayed enrollment or operational issues.
  • Accell Oncology Specialized oncology-focused clinical trial services division of Accell, including solid tumor and hematologic malignancy trials, advisory boards, and consultancy services with oncology key opinion leaders, supported by a network of 150+ oncology sites.
  • OncoForum Online oncology platform for organizing advisory boards and providing consultancy services with oncology key opinion leaders (KOLs), enabling virtual meetings to obtain expert validation on medical and trial design topics for pharmaceutical and biotech clients.

Companies that use Accell

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles2 records

Accell technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Accell partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • Syntax for SciencecoreStrategic or Co-development Partner · 1 November 2019Strategic CRO partnership announced in November 2019 combining Accell's Eastern European expertise with Syntax's Spanish operations - described as 'East meets West' collaboration
  • Wuhan National Bio-industry Base (Biolake)minorStrategic or Co-development Partner · 1 August 2018Meeting with Chinese biotech industrial base delegation in St. Petersburg; Biolake expressed interest in collaboration given Accell's oncology expertise and connections with key opinion leaders in Eastern Europe
  • American CRO PartnerminorStrategic or Co-development Partner · 1 July 2017During Boston conference, Julia Kondakov and Maria Mezentseva visited American CRO's office to discuss partnership grounds; companies had collaborated on projects before
  • Maximax Pharmaceutical Research Inc. (MPR)minorStrategic or Co-development Partner · 1 January 2011Accell joined MPR's Global CRO Development Group strategic alliance with other regional CROs (Cromos Pharma, Fortis Clinical Research, Research Development RA) to expand scale, scope and geographic locations
  • Cromos PharmaminorStrategic or Co-development PartnerPart of MPR CRO Alliance - USA-based CEE CRO partner in the global strategic alliance
  • Fortis Clinical Research (India)minorStrategic or Co-development PartnerPart of MPR CRO Alliance - India-based CRO partner in the global strategic alliance
  • Research Development RA S.A. (South America)minorStrategic or Co-development PartnerPart of MPR CRO Alliance - South America-based CRO partner in the global strategic alliance

Scale indicators10 records

Recent moves9 records

Expansion highlights6 records

Accell competitors and assessment

Company assessment

Direct peers

  • Cromos Pharma: US-based CRO focused on Central and Eastern Europe with similar regional specialization. Cromos is also a member of the same Maximax Global CRO Alliance with Accell, making it both a partner and the closest direct competitor for CEE oncology and multi-therapeutic trials.
  • Worldwide Clinical Trials: Mid-size, full-service global CRO with comparable therapeutic-area focus (oncology, cardiology, CNS) and a similar emphasis on scientific quality and sponsor relationships. Directly competes for mid-cap biotech and large pharma Phase II-IV work.
  • Fortis Clinical Research: India-based full-service CRO that is also a partner in the Maximax Global CRO Alliance with Accell. Comparable as a regional-specialist CRO serving global sponsors, with similar cost-arbitrage positioning and Phase I-IV offerings.

Broad incumbents

  • Medpace: Mid-to-large full-service CRO with strong therapeutic specialization and reputation for high-quality data. While larger and globally distributed, Medpace is a relevant comparable for Accell's physician-led, therapeutically-aligned operating model.
  • IQVIA: Largest global CRO with integrated technology, real-world data, and full Phase I-IV capabilities. Competes with Accell for enterprise pharma trials and increasingly absorbs regional specialists via acquisition, defining the upper-bound competitive threat.
  • ICON plc: Global full-service CRO formed via major consolidations (PRA merger), offering biotech and large pharma sponsors end-to-end clinical and post-approval services. Represents the scaled, technology-enabled alternative to Accell's regional specialist model.
  • Parexel: Large global CRO with comprehensive Phase I-IV services and strong oncology/biotech franchise post EQT-Goldman take-private. Provides a useful scaled benchmark for what Accell would need to evolve into to compete for multinational trial RFPs.
  • Syneos Health: Large CRO and commercialization services provider offering end-to-end clinical development plus commercial solutions. Competitor for large enterprise pharma trial RFPs where Accell might serve as a regional sub-contractor.

Emerging players

  • Tigermed (Hangzhou Tigermed): Leading China-based CRO expanding internationally with comparable therapeutic specialization (oncology) and growing EU/US footprint. Represents an emerging non-Western competitor for global sponsors seeking cost-effective, regionalized trial execution.

Regional players

  • Clinical Research Services (CRS): European CRO focused on early-phase and bioequivalence studies with strong presence in Germany and broader EU. Relevant as a regional European CRO comparable to Accell's EU expansion strategy post-Russia/Ukraine exit.

Market position

Strengths6 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Accell social profiles

Digital presence

Accell compliance and trust

Trust signal

Compliance1 record

Accell financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Accell leadership team

Management profile

Number of profiles

Profiles9 records

Accell subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Accell funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Accell M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Accell

What does Accell do?

Accell Clinical Research is a full-service Contract Research Organization (CRO) that manages Phase I-IV clinical trials for pharmaceutical and biotech sponsors across Eastern Europe, Russia, and CIS countries. Its core offerings include clinical trial management, functional outsourcing of clinical research staff, strategic guidance and trial set-up (feasibility, site selection, regulatory affairs), and rescue studies for delayed trials. Through its Accell Oncology sub-brand, it operates the only oncology-specialized CRO division in Eastern Europe and Russia, supplemented by the OncoForum online platform for virtual advisory boards with oncology key opinion leaders.

Is Accell a public or private company?

Accell is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Accell founded?

Accell was founded in 2007. It employs 11 to 50 people.

Where is Accell based?

Accell is headquartered in Warrenton, United States, in the North America region.

How does Accell make money?

One revenue line is on record: clinical Research Services.

Who are Accell's main competitors?

Direct peers on record are Cromos Pharma, Worldwide Clinical Trials and Fortis Clinical Research. Broad incumbents are Medpace, IQVIA, ICON plc, Parexel and Syneos Health. Tigermed (Hangzhou Tigermed) is listed as an emerging player. Clinical Research Services (CRS) is listed as a regional player.

Does Accell have an API?

No public API is recorded for Accell.

What industry is Accell in?

Accell's product category is Contract Research Organization (Clinical Trial Services). Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BloombergKKR Admits Defeat on Its Pricey Pandemic Bike BetKKR-led consortium acquired Dutch bike manufacturer Accell Group in 2022 for approximately €1.6 billion, paying a more than 25% premium, betting that pandemic-era cycling demand would persist; after demand cooled and inventory glutmed, the company required a 40% debt reduction restructuring in early 2025 and €235 million cash injection, which proved insufficient. This week KKR agreed to hand Accell to its lenders along with a €30 million parting cash injection, with lenders writing off around €850 million in loans while €270 million in super-senior financing remains in place. The deal underscores how swiftly leveraged buyouts can unravel under rising interest rates and cyclical demand shifts, marking the company's second restructuring in little over a year.openPR.comRegulatory Affairs Outsourcing Market See Strong Future Growth By 2032 | Accell Clinical Research, LLC, Genpact, CRITERIUMCoherent Market Insights released a report projecting the global regulatory affairs outsourcing market will grow from USD 9.33 billion in 2025 to USD 19.26 billion by 2032, at a CAGR of 10.9%. The analysis highlights key industry players including Accell Clinical Research, Genpact, and CRITERIUM as major participants in this expanding sector. This forecast is driven by rising industry demand, expanding applications, and technological advancements within the pharmaceutical and medical device industries.JjccgroupRegulatory Outsourcing Services: A Complete GuideThis article serves as a comprehensive guide for small and growing businesses on the strategic benefits of outsourcing regulatory affairs to specialized firms. It outlines key advantages such as cost savings, access to specialized expertise, risk reduction, and accelerated time-to-market for products in regulated industries like life sciences. The text also provides criteria for selecting partners and highlights specific providers including J&JCC Group, Accell Clinical Research, Genpact, and Charles River Laboratories.openPR.comClinical Trials Market Study On Growth Factors For 2019-2025: Eli Lilly and Company, PAREXEL, Pfizer, ICON plc, Novo NordiskPharmaceutical Development Services Ltd, Accell Clinical Research, Covance,The global clinical trials market is projected to grow from USD 1.04 billion in 2017 to USD 1.76 billion by 2025, a CAGR of 6.7%. Key developments include the CARMELINA trial meeting its primary endpoint and AAIPharma rebranding as Alcami.